Q3 EPS Estimates for DENTSPLY SIRONA Cut by Zacks Research

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Investment analysts at Zacks Research reduced their Q3 2025 earnings estimates for DENTSPLY SIRONA in a research report issued to clients and investors on Thursday, May 29th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.46 per share for the quarter, down from their previous forecast of $0.49. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q1 2027 earnings at $0.39 EPS and FY2027 earnings at $2.23 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The business had revenue of $879.00 million for the quarter, compared to analyst estimates of $854.75 million. During the same period in the prior year, the firm earned $0.42 earnings per share. DENTSPLY SIRONA’s revenue was down 7.8% on a year-over-year basis.

Several other research analysts also recently weighed in on the stock. UBS Group lowered their price objective on shares of DENTSPLY SIRONA from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Mizuho lowered their price objective on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a “neutral” rating on the stock in a report on Thursday, March 13th. Morgan Stanley downgraded shares of DENTSPLY SIRONA from an “overweight” rating to an “equal weight” rating and set a $14.00 target price for the company. in a report on Tuesday, April 15th. Piper Sandler lowered their target price on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Thursday, March 13th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.36.

DENTSPLY SIRONA Stock Performance

XRAY opened at $15.89 on Monday. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72. The company’s fifty day moving average price is $14.53 and its two-hundred day moving average price is $17.00. DENTSPLY SIRONA has a 1-year low of $12.16 and a 1-year high of $28.24. The company has a market cap of $3.17 billion, a price-to-earnings ratio of -7.68, a PEG ratio of 1.80 and a beta of 0.92.

DENTSPLY SIRONA Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Investors of record on Friday, June 27th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $0.64 annualized dividend and a yield of 4.03%. DENTSPLY SIRONA’s payout ratio is currently -14.10%.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in DENTSPLY SIRONA by 27.9% during the fourth quarter. Bank of New York Mellon Corp now owns 2,403,110 shares of the medical instruments supplier’s stock worth $45,611,000 after purchasing an additional 523,692 shares during the period. Charles Schwab Investment Management Inc. raised its stake in DENTSPLY SIRONA by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,101,133 shares of the medical instruments supplier’s stock valued at $39,880,000 after purchasing an additional 35,360 shares in the last quarter. Barclays PLC raised its stake in DENTSPLY SIRONA by 21.8% in the third quarter. Barclays PLC now owns 306,809 shares of the medical instruments supplier’s stock valued at $8,301,000 after purchasing an additional 54,920 shares in the last quarter. Canvas Wealth Advisors LLC raised its stake in shares of DENTSPLY SIRONA by 126.5% during the fourth quarter. Canvas Wealth Advisors LLC now owns 326,298 shares of the medical instruments supplier’s stock worth $6,245,000 after acquiring an additional 182,234 shares in the last quarter. Finally, Entropy Technologies LP purchased a new position in shares of DENTSPLY SIRONA during the fourth quarter worth approximately $630,000. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.